{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T19:28:18Z","timestamp":1794684498081,"version":"4.9.1"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:00:00Z","timestamp":1771545600000},"content-version":"vor","delay-in-days":23,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Women's Health"],"DOI":"10.1186\/s12905-026-04262-z","type":"journal-article","created":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T10:54:49Z","timestamp":1769597689000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The role of mifepristone in managing myoma: a systematic review and meta-analysis of uterine parameters"],"prefix":"10.1186","volume":"26","author":[{"given":"Pouyan","family":"Ebrahimi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimia","family":"Pakdaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amin","family":"Esmaeilnia Shirvani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seema","family":"Advani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Farmahini Farahani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sima","family":"Elyasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malihe","family":"Nourollahpour Shiadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,28]]},"reference":[{"key":"4262_CR1","doi-asserted-by":"crossref","unstructured":"Lewis TD, Malik M, Britten J, San Pablo AM, Catherino WH. A Comprehensive Review of the Pharmacologic Management of Uterine Leiomyoma. Biomed Res Int 2018, 2018:2414609.","DOI":"10.1155\/2018\/2414609"},{"issue":"21","key":"4262_CR2","doi-asserted-by":"publisher","first-page":"2583","DOI":"10.1097\/CM9.0000000000002971","volume":"137","author":"Y Dai","year":"2024","unstructured":"Dai Y, Chen H, Yu J, Cai J, Lu B, Dai M, Zhu L. Global and regional trends in the incidence and prevalence of uterine fibroids and attributable risk factors at the National level from 2010 to 2019: A worldwide database study. Chin Med J (Engl). 2024;137(21):2583\u20139.","journal-title":"Chin Med J (Engl)"},{"issue":"D8","key":"4262_CR3","first-page":"198","volume":"1","author":"V Sarkisova","year":"2022","unstructured":"Sarkisova V, Xegay R. Causes, Diagnosis, Conservative and operative treatment of uterine Myoma. Sci Innov. 2022;1(D8):198\u2013203.","journal-title":"Sci Innov"},{"issue":"2","key":"4262_CR4","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1055\/s-0037-1599090","volume":"35","author":"MM McWilliams","year":"2017","unstructured":"McWilliams MM, Chennathukuzhi VM. Recent advances in uterine fibroid etiology. Semin Reprod Med. 2017;35(2):181\u20139.","journal-title":"Semin Reprod Med"},{"key":"4262_CR5","doi-asserted-by":"crossref","unstructured":"Kalyan S, Sharma S. Giant uterine leiomyoma: a case report with literature review. Int J Reprod Contracept Obstet Gynecol. 2018;7(11).","DOI":"10.18203\/2320-1770.ijrcog20184548"},{"issue":"3","key":"4262_CR6","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1111\/j.1542-2011.2012.00176.x","volume":"57","author":"KE Rice","year":"2012","unstructured":"Rice KE, Secrist JR, Woodrow EL, Hallock LM, Neal JL. Etiology, diagnosis, and management of uterine leiomyomas. J Midwifery Womens Health. 2012;57(3):241\u20137.","journal-title":"J Midwifery Womens Health"},{"issue":"1","key":"4262_CR7","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1002\/ijgo.15136","volume":"165","author":"A Raffone","year":"2024","unstructured":"Raffone A, Raimondo D, Neola D, Travaglino A, Giorgi M, Lazzeri L, De Laurentiis F, Carravetta C, Zupi E, Seracchioli R, et al. Diagnostic accuracy of MRI in the differential diagnosis between uterine leiomyomas and sarcomas: A systematic review and meta-analysis. Int J Gynaecol Obstet. 2024;165(1):22\u201333.","journal-title":"Int J Gynaecol Obstet"},{"key":"4262_CR8","doi-asserted-by":"crossref","unstructured":"Ferrari F, Forte S, Valenti G, Ardighieri L, Barra F, Esposito V, Sartori E, Odicino F. Current treatment options for cervical leiomyomas: a systematic review of literature. Med (Kaunas). 2021;57(2):92.","DOI":"10.3390\/medicina57020092"},{"issue":"2","key":"4262_CR9","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S1701-2163(15)30338-8","volume":"37","author":"GA Vilos","year":"2015","unstructured":"Vilos GA, Allaire C, Laberge PY, Leyland N. The management of uterine leiomyomas. J Obstet Gynaecol Can. 2015;37(2):157\u201378.","journal-title":"J Obstet Gynaecol Can"},{"issue":"4","key":"4262_CR10","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1177\/1933719111432867","volume":"19","author":"M Sabry","year":"2012","unstructured":"Sabry M, Al-Hendy A. Medical treatment of uterine leiomyoma. Reprod Sci. 2012;19(4):339\u201353.","journal-title":"Reprod Sci"},{"key":"4262_CR11","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.bpobgyn.2015.11.016","volume":"34","author":"BN Kashani","year":"2016","unstructured":"Kashani BN, Centini G, Morelli SS, Weiss G, Petraglia F. Role of medical management for uterine leiomyomas. Best Pract Res Clin Obstet Gynaecol. 2016;34:85\u2013103.","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"issue":"8","key":"4262_CR12","first-page":"e28318","volume":"14","author":"ZV Karena","year":"2022","unstructured":"Karena ZV, Shah H, Vaghela H, Chauhan K, Desai PK, Chitalwala AR. Clinical utility of mifepristone: apprising the expanding horizons. Cureus. 2022;14(8):e28318.","journal-title":"Cureus"},{"issue":"5","key":"4262_CR13","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.contraception.2009.12.012","volume":"82","author":"IM Spitz","year":"2010","unstructured":"Spitz IM. Mifepristone: where do we come from and where are we going? Clinical development over a quarter of a century. Contraception. 2010;82(5):442\u201352.","journal-title":"Contraception"},{"issue":"2","key":"4262_CR14","doi-asserted-by":"publisher","first-page":"98","DOI":"10.5005\/jp-journals-10006-2398","volume":"16","author":"K Kumari","year":"2024","unstructured":"Kumari K, Malik R, Hada A, Goel H. Effectiveness of low dose mifepristone in medical management of fibroids. J South Asian Federation Obstet Gynecol. 2024;16(2):98\u2013102.","journal-title":"J South Asian Federation Obstet Gynecol"},{"issue":"3","key":"4262_CR15","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1007\/s13224-023-01903-3","volume":"74","author":"S Desai","year":"2024","unstructured":"Desai S, Oswal S, Patel C, Parikh R. To evaluate the efficacy and safety of mifepristone in reducing the size & symptoms of uterine Leiomyoma\/Fibroids. J Obstet Gynaecol India. 2024;74(3):250\u20135.","journal-title":"J Obstet Gynaecol India"},{"key":"4262_CR16","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.jclinepi.2021.02.003","volume":"134","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Moher D. Updating guidance for reporting systematic reviews: development of the PRISMA 2020 statement. J Clin Epidemiol. 2021;134:103\u201312.","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"4262_CR17","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1186\/s12874-024-02356-6","volume":"24","author":"A Abbas","year":"2024","unstructured":"Abbas A, Hefnawy MT, Negida A. Meta-analysis accelerator: a comprehensive tool for statistical data conversion in systematic reviews with meta-analysis. BMC Med Res Methodol. 2024;24(1):243.","journal-title":"BMC Med Res Methodol"},{"key":"4262_CR18","unstructured":"Effect Size Calculator. Cambridge University, Press. & Assessment. [https:\/\/www.cambridge.org\/insight\/effect-size-calculator]"},{"key":"4262_CR19","unstructured":"Cambridge Centre for Evaluation & Monitoring. Effect Size Calculator. Date Accessed [December 6, 2024]. https:\/\/www.cem.org\/effect-size-calculator"},{"issue":"2","key":"4262_CR20","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1093\/jnci\/81.2.107","volume":"81","author":"CB Begg","year":"1989","unstructured":"Begg CB, Berlin JA. Publication bias and dissemination of clinical research. J Natl Cancer Inst. 1989;81(2):107\u201315.","journal-title":"J Natl Cancer Inst"},{"issue":"7651","key":"4262_CR21","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1136\/bmj.39490.551019.BE","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, Sch\u00fcnemann HJ. What is quality of evidence and why is it important to clinicians? BMJ. 2008;336(7651):995\u20138.","journal-title":"BMJ"},{"key":"4262_CR22","unstructured":"Rani S, Kiran C, ROLE OF LOW DOSE OF MIFEPRISTONE IN MANAGEMENT OF FIBROID IN PERIMENOPAUSAL WOMEN. : A COMPARATIVE STUDY. Age (in years), 45(2.71):43.70-42.41."},{"key":"4262_CR23","unstructured":"Saxena R, Goyal R, Jain R. Effects of low dose oral mifepristone on uterine fibroids. Indian Obstet Gynecol. 2019;9(4):38\u201342."},{"issue":"57","key":"4262_CR24","doi-asserted-by":"publisher","first-page":"9990","DOI":"10.14260\/jemds\/2015\/1444","volume":"4","author":"R Lal","year":"2015","unstructured":"Lal R, Ashwini A, Lal S. Role of low dose mifepristone in the treatment of symptomatic fibroid uterus: a double control randomized control trial. J Evol Med Dent Sci. 2015;4(57):9990\u201310001.","journal-title":"J Evol Med Dent Sci"},{"issue":"1","key":"4262_CR25","doi-asserted-by":"publisher","first-page":"361","DOI":"10.2147\/IJWH.S42770","volume":"5","author":"JLC Esteve","year":"2013","unstructured":"Esteve JLC, Acosta R, P\u00e9rez Y, Rodriguez B, Seigler I, Sanchez C, Tomasi G. Mifepristone versus placebo to treat uterine myoma: A double-blind, randomized clinical trial. Int J Women\u2019s Health. 2013;5(1):361\u20139.","journal-title":"Int J Women\u2019s Health"},{"key":"4262_CR26","doi-asserted-by":"crossref","unstructured":"Carbonell JL, Acosta R, P\u00e9rez Y, Marrero AG, Trellez E, S\u00e1nchez C, Tomasi G. Safety and effectiveness of different dosage of mifepristone for the treatment of uterine fibroids: a double-blind randomized clinical trial. Int J Womens Health. 2013;5:115\u201324.","DOI":"10.2147\/IJWH.S33125"},{"key":"4262_CR27","doi-asserted-by":"crossref","unstructured":"Carbonell JL, Acosta R, P\u00e9rez Y, Garc\u00e9s R, S\u00e1nchez C, Tomasi G. Treatment of uterine myoma with 2.5 or 5\u00a0mg mifepristone daily during 3 months with 9 months posttreatment followup: Randomized clinical trial. ISRN Obstetrics and Gynecology 2013, 2013.","DOI":"10.1155\/2013\/649030"},{"issue":"2","key":"4262_CR28","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.ejogrb.2011.12.018","volume":"161","author":"JLC Esteve","year":"2012","unstructured":"Esteve JLC, Acosta R, P\u00e9rez Y, Campos R, Hern\u00e1ndez AV, Texid\u00f3 CS. Treatment of uterine Myoma with 5 or 10\u00a0mg mifepristone daily during 6 months, post-treatment evolution over 12 months: Double-blind randomised clinical trial. Eur J Obstet Gynecol Reproductive Biology. 2012;161(2):202\u20138.","journal-title":"Eur J Obstet Gynecol Reproductive Biology"},{"issue":"1","key":"4262_CR29","doi-asserted-by":"publisher","first-page":"75","DOI":"10.2147\/IJWH.S28103","volume":"4","author":"JL Carbonell Esteve","year":"2012","unstructured":"Carbonell Esteve JL, River\u00f3n AM, Cano M, Ortiz AI, Valle A, Texid\u00f3 CS, Tomasi G. Mifepristone 2.5\u00a0mg versus 5\u00a0mg daily in the treatment of leiomyoma before surgery. Int J Women\u2019s Health. 2012;4(1):75\u201384.","journal-title":"Int J Women\u2019s Health"},{"issue":"2","key":"4262_CR30","first-page":"130","volume":"36","author":"JL Carbonell Esteve","year":"2010","unstructured":"Carbonell Esteve JL, Acosta R, Heredia B, P\u00e9rez Y, Yero Casta\u00f1eda MC, Seigler I, Andreu Ballester JC. Mifepristona Para Tratamiento Del fibroma Uterino. Revista Cubana De Obstet Y Ginecolog\u00eda. 2010;36(2):130\u201344.","journal-title":"Revista Cubana De Obstet Y Ginecolog\u00eda"},{"issue":"2","key":"4262_CR31","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.pog.2009.11.001","volume":"53","author":"JL Carbonell Esteve","year":"2010","unstructured":"Carbonell Esteve JL, Quir\u00f3z Ram\u00edrez GM, Borge A, Castell\u00f3n Zapata LE, Arag\u00f3n WC, Tomasi G. 5\u00a0mg versus 10\u00a0mg mifepristone daily in the treatment of leiomyoma: A randomised clinical trial. Progresos De Obstet Y Ginecol. 2010;53(2):51\u20138.","journal-title":"Progresos De Obstet Y Ginecol"},{"issue":"1","key":"4262_CR32","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/j.1479-828X.2008.00931.x","volume":"49","author":"M Bagaria","year":"2009","unstructured":"Bagaria M, Suneja A, Vaid NB, Guleria K, Mishra K. Low-dose mifepristone in treatment of uterine leiomyoma: A randomised double\u2010blind placebo\u2010controlled clinical trial. Aust N Z J Obstet Gynaecol. 2009;49(1):77\u201383.","journal-title":"Aust N Z J Obstet Gynaecol"},{"issue":"5","key":"4262_CR33","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1097\/AOG.0b013e31818aa930","volume":"112","author":"JLC Esteve","year":"2008","unstructured":"Esteve JLC, Acosta R, Heredia B, Perez Y, Casta\u00f1eda MCY, Hern\u00e1ndez AV. Mifepristone for the treatment of uterine leiomyomas A randomized controlled trial. Obstet Gynecol. 2008;112(5):1029\u201336.","journal-title":"Obstet Gynecol"},{"issue":"6","key":"4262_CR34","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1097\/01.AOG.0000243776.23391.7b","volume":"108","author":"K Fiscella","year":"2006","unstructured":"Fiscella K, Eisinger SH, Meldrum S, Feng C, Fisher SG, Guzick DS. Effect of mifepristone for symptomatic leiomyomata on quality of life and uterine size: a randomized controlled trial. Obstet Gynecol. 2006;108(6):1381\u20137.","journal-title":"Obstet Gynecol"},{"issue":"2","key":"4262_CR35","first-page":"243","volume":"101","author":"SH Eisinger","year":"2003","unstructured":"Eisinger SH, Meldrum S, Fiscella K, le Roux HD, Guzick DS. Low-dose mifepristone for uterine leiomyomata. Obstet Gynecol. 2003;101(2):243\u201350.","journal-title":"Obstet Gynecol"},{"issue":"6","key":"4262_CR36","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1016\/j.fertnstert.2013.08.039","volume":"100","author":"Q Shen","year":"2013","unstructured":"Shen Q, Hua Y, Jiang W, Zhang W, Chen M, Zhu X. Effects of mifepristone on uterine leiomyoma in premenopausal women: a meta-analysis. Fertil Steril. 2013;100(6):1722\u2013e17261721.","journal-title":"Fertil Steril"},{"issue":"6","key":"4262_CR37","doi-asserted-by":"publisher","first-page":"72","DOI":"10.33545\/gynae.2020.v4.i6b.734","volume":"4","author":"DV Jayashree","year":"2020","unstructured":"Jayashree DV, Mallika DA, Roopa DK. Mifepristone for medical management of leiomyomata uteri: A prospective study. Int J Clin Obstet Gynecol. 2020;4(6):72\u20136.","journal-title":"Int J Clin Obstet Gynecol"},{"key":"4262_CR38","doi-asserted-by":"crossref","unstructured":"Hangarga U. D R: Low dose mifepristone in the treatment of uterine leiomyoma. Int J Reprod Contracept Obstet Gynecol. 2016;6(1):44\u20138.","DOI":"10.18203\/2320-1770.ijrcog20164498"},{"issue":"2","key":"4262_CR39","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.ijgo.2009.11.019","volume":"109","author":"C Feng","year":"2010","unstructured":"Feng C, Meldrum S, Fiscella K. Improved quality of life is partly explained by fewer symptoms after treatment of fibroids with mifepristone. Int J Gynaecol Obstet. 2010;109(2):121\u20134.","journal-title":"Int J Gynaecol Obstet"},{"issue":"2","key":"4262_CR40","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.ejogrb.2011.12.018","volume":"161","author":"JL Esteve","year":"2012","unstructured":"Esteve JL, Acosta R, P\u00e9rez Y, Campos R, Hern\u00e1ndez AV, Texid\u00f3 CS. Treatment of uterine Myoma with 5 or 10\u00a0mg mifepristone daily during 6 months, post-treatment evolution over 12 months: double-blind randomised clinical trial. Eur J Obstet Gynecol Reprod Biol. 2012;161(2):202\u20138.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"5","key":"4262_CR41","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1097\/AOG.0b013e31818aa930","volume":"112","author":"JL Carbonell Esteve","year":"2008","unstructured":"Carbonell Esteve JL, Acosta R, Heredia B, Perez Y, Castaneda MC, Hernandez AV. Mifepristone for the treatment of uterine leiomyomas: a randomized controlled trial. Obstet Gynecol. 2008;112(5):1029\u201336.","journal-title":"Obstet Gynecol"},{"key":"4262_CR42","doi-asserted-by":"crossref","unstructured":"Murji A, Whitaker L, Chow TL, Sobel ML. Selective progesterone receptor modulators (SPRMs) for uterine fibroids. Cochrane Database Syst Rev. 2017;4(4):CD010770.","DOI":"10.1002\/14651858.CD010770.pub2"},{"issue":"2","key":"4262_CR43","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.fertnstert.2024.02.046","volume":"122","author":"G Milewska","year":"2024","unstructured":"Milewska G, Ponikwicka\u2013Tyszko D, Bernaczyk P, Lupu O, Szamatowicz M, Sztachelska M, Pilaszewicz-Puza A, Koda M, Bielawski T, Zbucka-Kretowska M. Functional evidence for two distinct mechanisms of action of progesterone and selective progesterone receptor modulator on uterine leiomyomas. Fertil Steril. 2024;122(2):341\u201351.","journal-title":"Fertil Steril"},{"issue":"8","key":"4262_CR44","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.3390\/cells12081117","volume":"12","author":"M Ali","year":"2023","unstructured":"Ali M, Ciebiera M, Vafaei S, Alkhrait S, Chen H-Y, Chiang Y-F, Huang K-C, Feduniw S, Hsia S-M, Al-Hendy A. Progesterone signaling and uterine fibroid pathogenesis; molecular mechanisms and potential therapeutics. Cells. 2023;12(8):1117.","journal-title":"Cells"},{"key":"4262_CR45","doi-asserted-by":"crossref","unstructured":"Maheshwari DB, Mittal DS, Prabhakar DM, Sharma DP. Role of low dose mifepristone in management of uterine fibroid. Int J Clin Obstet Gynecol. 2021;5(1):397\u2013400.","DOI":"10.33545\/gynae.2021.v5.i1g.843"},{"key":"4262_CR46","doi-asserted-by":"crossref","unstructured":"Jain D. Mifepristone therapy in symptomatic leiomyomata using a variable dose pattern with a favourable outcome. J Mid-life Health. 2018;9(2):65\u201371.","DOI":"10.4103\/jmh.JMH_100_17"},{"key":"4262_CR47","doi-asserted-by":"publisher","first-page":"115","DOI":"10.2147\/IJWH.S33125","volume":"5","author":"JL Carbonell","year":"2013","unstructured":"Carbonell JL, Acosta R, Perez Y, Marrero AG, Trellez E, Sanchez C, Tomasi G. Safety and effectiveness of different dosage of mifepristone for the treatment of uterine fibroids: a double-blind randomized clinical trial. Int J Womens Health. 2013;5:115\u201324.","journal-title":"Int J Womens Health"},{"key":"4262_CR48","doi-asserted-by":"crossref","unstructured":"Marimuthu S, Gopalan* U. Efficacy of different doses of mifepristone in the management of uterine leiomyoma in a tertiary care centre. Indian J Obstet Gynecol Res. 2023;10(3).","DOI":"10.18231\/j.ijogr.2023.056"},{"key":"4262_CR49","doi-asserted-by":"crossref","unstructured":"Baird DT, Brown A, Critchley HOD, Williams AR, Lin S, Cheng L. Effect of long-term treatment with low\u2010dose mifepristone on the endometrium. Hum Reprod. 2023;18(1):61\u20138.","DOI":"10.1093\/humrep\/deg022"},{"issue":"2","key":"4262_CR50","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S1701-2163(15)30338-8","volume":"37","author":"GA Vilos","year":"2015","unstructured":"Vilos GA, Allaire C, Laberge P-Y, Leyland N, Vilos AG, Murji A, Chen I. The management of uterine leiomyomas. J Obstet Gynecol Can. 2015;37(2):157\u201378.","journal-title":"J Obstet Gynecol Can"},{"issue":"3","key":"4262_CR51","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1046\/j.1365-2265.2001.01026.x","volume":"54","author":"RS Newfield","year":"2001","unstructured":"Newfield RS, Spitz IM, Isacson C, New MI. Long-term mifepristone (RU486) therapy resulting in massive benign endometrial hyperplasia. Clin Endocrinol. 2001;54(3):399\u2013404.","journal-title":"Clin Endocrinol"},{"key":"4262_CR52","doi-asserted-by":"crossref","unstructured":"Lin Q, Zhou Y. Endometrial changes associated with mifepristone: a review. Int J Gen Med. 2025;18:5503\u20138.","DOI":"10.2147\/IJGM.S535797"},{"issue":"8","key":"4262_CR53","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1093\/humrep\/dep100","volume":"24","author":"M Engman","year":"2009","unstructured":"Engman M, Granberg S, Williams AR, Meng CX, Lalitkumar PG, Gemzell-Danielsson K. Mifepristone for treatment of uterine leiomyoma. A prospective randomized placebo controlled trial. Hum Reprod. 2009;24(8):1870\u20139.","journal-title":"Hum Reprod"},{"issue":"2","key":"4262_CR54","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.fertnstert.2013.10.015","volume":"101","author":"GM Yerushalmi","year":"2014","unstructured":"Yerushalmi GM, Gilboa Y, Jakobson-Setton A, Tadir Y, Goldchmit C, Katz D, Seidman DS. Vaginal mifepristone for the treatment of symptomatic uterine leiomyomata: an open-label study. Fertil Steril. 2014;101(2):496\u2013500.","journal-title":"Fertil Steril"},{"issue":"5","key":"4262_CR55","first-page":"317","volume":"56","author":"ML Bian","year":"2021","unstructured":"Bian ML, Huang ML, Zhang ZY, Liu SM, Sun J, Fang F, Gu YP, Liu CD, Yao C. [Preoperative treatment of uterine fibroids with low-dose mifepristone: a multicenter, randomized, double-blind, placebo-controlled, parallel-group study]. Zhonghua Fu Chan Ke Za Zhi. 2021;56(5):317\u201327.","journal-title":"Zhonghua Fu Chan Ke Za Zhi"}],"container-title":["BMC Women's Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12905-026-04262-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-026-04262-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-026-04262-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T14:04:29Z","timestamp":1771596269000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12905-026-04262-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,28]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4262"],"URL":"https:\/\/doi.org\/10.1186\/s12905-026-04262-z","relation":{},"ISSN":["1472-6874"],"issn-type":[{"value":"1472-6874","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,28]]},"assertion":[{"value":"10 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable due to secondary data analysis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"128"}}